NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.
References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application.
















